Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study.
暂无分享,去创建一个
A. Naranjo | J. Geiger | S. Grupp | L. Diller | D. Haas-Kogan | W. London | S. Braunstein | S. Voss | S. Kreissman | Julie R. Park | S. DuBois | G. Khanna | Kevin X. Liu | J. Doski | Fan F Zhang
[1] A. Naranjo,et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. , 2019, JAMA.
[2] K. Matthay,et al. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high‐risk neuroblastoma: A report from the COG A3973 study , 2019, Pediatric blood & cancer.
[3] S. Groshen,et al. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial , 2018, Pediatric blood & cancer.
[4] A. Naranjo,et al. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 , 2018, Front. Immunol..
[5] S. Jason,et al. Neuroblastoma , 2018, Definitions.
[6] N. Cheung,et al. Dose‐escalation is needed for gross disease in high‐risk neuroblastoma , 2018, Pediatric blood & cancer.
[7] F. Berthold,et al. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months , 2017, BMC Cancer.
[8] D. Haas-Kogan,et al. A Cautionary Tale: Risks of Radiation Therapy De-Escalation in Pediatric Malignancies. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Bradley A George,et al. Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement. , 2017, International journal of radiation oncology, biology, physics.
[10] R. Hawkins,et al. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. , 2017, International journal of radiation oncology, biology, physics.
[11] D. von Allmen,et al. Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Versteeg,et al. DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells , 2015, PloS one.
[13] P. Tam,et al. Is complete resection of high-risk stage IV neuroblastoma associated with better survival? , 2015, Journal of pediatric surgery.
[14] Gudrun Schleiermacher,et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Jenkner,et al. Local control in metastatic neuroblastoma in children over 1 year of age , 2015, BMC Cancer.
[16] S. Groshen,et al. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma , 2015, Clinical Cancer Research.
[17] John M Maris,et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[18] F. Berthold,et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Matthay,et al. Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. , 2011, Cancer letters.
[20] Swati S. More,et al. Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model Systems , 2011, Clinical Cancer Research.
[21] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[22] B. Hero,et al. Neuroblastoma , 2007, The Lancet.
[23] R. Müller,et al. Intensified External-Beam Radiation Therapy Improves the Outcome of Stage 4 Neuroblastoma in Children > 1 Year with Residual Local Disease , 2006, Strahlentherapie und Onkologie.
[24] D. Hawkins,et al. Fractionated low‐dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high‐risk neuroblastoma , 2004, Cancer.
[25] N. Cheung,et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. , 2004, Journal of pediatric surgery.
[26] D. Stram,et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. , 2003, International journal of radiation oncology, biology, physics.
[27] G. Heller,et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. LaQuaglia,et al. Local control with multimodality therapy for stage 4 neuroblastoma. , 2000, International journal of radiation oncology, biology, physics.
[29] E. Halperin. Long‐term results of therapy for stage C neuroblastoma , 1996, Journal of surgical oncology.
[30] D. Stram,et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Sallan,et al. Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[33] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .